


0207.2

syngenta

Parkinson's Disease

What can Syngenta say about the issue?



Botham, Philip
Exhibit_88
6/18/2020

SYNG-PQ-00481037

The Issue

Paraquat exposure has been implicated in the literature as a potential contributory factor in Parkinson's disease (PD) in humans.

- There is a chemical structure association made in the literature between paraquat and MPTP
 - shown to induce symptomology of Parkinson's disease in humans
- There are literature epidemiology reports of an association between working with pesticides (and paraquat) and Parkinson's disease
- There are literature reports of an experimental model for PD in the C57Bl6 mouse where paraquat administered intraperitoneally causes a reduction in the number of neurones in the brain, together with in some studies a reduction in levels of dopamine in the brain and behavioural changes

2

syngenta

SYNG-PQ-00481038

What we cannot say

- Paraquat does not enter the brain
- Paraquat does not cause any changes in the brain
- Paraquat only causes effects in the mouse
- The mouse data on paraquat are not relevant to humans
- People are not exposed to paraquat
- There are no data reporting that paraquat may be associated with PD in humans
- The data show that paraquat does not cause PD in humans

3

syngenta

SYNG-PQ-00481039

Current position

Epidemiology

- The evidence from case reports, case series and case-control studies is mixed and without consistent exposure-response or chemical-specific pattern.
- A major problem is the absence of detailed and validated exposure information.
- Currently, the data from epidemiology studies do not provide sufficient evidence to support a causal association between exposure to agricultural chemicals, including paraquat, and PD.

4

syngenta

SYNG-PQ-00481040

Current position

Animal studies

- The mouse has been developed as a sensitive investigative tool to examine chemicals for changes considered relevant to PD.
- Paraquat administered to the mouse by the intraperitoneal (ip) route leads to a limited reduction in neuronal cell number in the *S nigra*
- There are no consistent data from the mouse model indicating effects from paraquat dosing required as part of the progression and expression of PD (dopamine changes or behavioural effects).
- There is limited evidence for paraquat causing a reduction in neuronal cell number in species other than the mouse.
 - CTL has examined the rat using a protocol taken from the literature that claimed an effect. There was no reduction in neuronal cell number in our study.
- The relevance of the observations in this investigative model to humans who may be exposed to low levels of paraquat mainly by the dermal/oral route is considered to be limited
- There is no evidence that paraquat causes biological changes related to PD by a relevant route for human exposure, or at doses approaching those to which humans may be exposed.

Current position

Structural association with MPTP

- The structural association of paraquat to MPTP is superficial and is inappropriate for drawing any conclusions on potential similar activity in regard to PD


Ongoing work

- External labs will continue to generate and report data:
 - Epidemiology
 - Ag Health study USA
 - Farm workers (x2?) France
 - DEFRA (Geoparkinson study) UK
 - Animal studies
 - Di Monte
 - Corey Slechta
 - Others
- Syngenta
 - Evaluation of PQ in the rat (negative)
 - Kinetics of PQ uptake into the brain of the mouse

Study - Effects of Dosing PQ 1x / week for 3 weeks

TH⁺ cell counts in SNpc

Using modified stereology parameters and new set up – 24% ↓ TH⁺ cells (PQ) : 33% ↓ TH⁺ cells (MPTP):



Data represents mean ± SEM. Saline control group received 3 weekly i.p. injections of sterile saline, n=9; PQ group received 3 weekly injections of 10 mg/kg PQ dichloride, n=9; MPTP group received 10 daily injections of 20 mg/kg MPTP, n=9. Values analysed by one way ANOVA followed by Newman-Keuls post test **p<0.001

SYNG-PQ-00481045


Studies specifically focusing on paraquat

Study	Country	No. Exposed Cases/Total Cases	No. Exposed Controls/Total Controls	OR (95% CI)	P-Value
Hertzman 1990	Canada	4/57	0/122	NR	0.01
Hertzman 1994	Canada	6/127	4/124 (cardiac)	1.25 (0.34 – 4.63)	
			5/121 (voters)	1.11 (0.32 – 3.87)	
Seidler 1996	Germany	1/380	0/755	NR	NR
Liou 1997	Taiwan	31/120	22/240	3.22 (2.41 – 4.31)	< 0.01
Kuopio 1999	Finland	3/123	5/246	NR	NR
Engel 2001*	USA	20/49	NR	0.8 (0.5 – 1.3)	
Kamel 2001**	USA	?/55	?/22286	1.5 (0.7 – 3.0)	
Firestone 2005	USA	?/250	?/388	1.67 (0.22 – 12.76)	

*Cross-sectional study

**Conference presentation

SYNG-PQ-00481047



SYNG-PQ-00481046


Possible outcomes

TABLE 4. Ever use of specific pesticides by self-reported Parkinson's disease (PD) cases and controls identified in the Agricultural Health Study at enrollment in 1993-1997 (prevalent PD) or at follow-up in 1999-2003 (incident PD)*

Pesticide Classification	Chemical	Prevalent PD				Incident PD					
		Cases	Controls	OR (95% CI)	95% CI	Cases	Controls	OR (95% CI)	95% CI		
		No.	%	No.	%	No.	%	No.	%		
Herbicides	Chlorpyrifos	30	39	26.5/30	0.8	0.5, 1.5	34	49	17.3/39	1.1	0.6, 1.9
	Metolachlor	22	29	22.0/29	0.9	0.5, 1.8	30	45	14.8/45	1.3	0.7, 2.3
	Bentazone	26	35	23.8/37	0.9	0.5, 1.6	32	47	16.4/47	1.5	0.8, 2.8
	Dicamba	23	32	21.3/36	1.4	0.8, 2.6	17	25	13.6/27	0.7	0.4, 1.2
	Dinitrophenol	31	40	25.7/47	0.9	0.5, 1.6	32	48	17.4/48	1.7	1.0, 3.2
	Trihalo	19	25	20.6/31	0.9	0.5, 1.7	22	32	13.7/37	1.2	0.6, 2.1
	Imidazopyr	19	25	20.6/31	0.9	0.5, 1.7	22	32	13.7/37	1.2	0.6, 2.1
	Mixture	22	30	22.0/30	0.5	0.3, 0.9	28	41	15.2/41	1.1	0.6, 1.9
	Organophosphorus	45	55	46.8/67	1.0	0.6, 1.7	49	67	32.6/66	1.1	0.6, 2.0
	Phenoxycarboxylate	24-D	47	56	40.0/52	0.9	0.5, 1.8	49	68	25.1/68	1.0
Insecticides	2,4,5-Ti	16	22	9.8/24	1.3	0.9, 1.7	24	35	8.9/31	1.4	1.0, 3.3
	2,4,5-Ti	4	5	4.2/29	0.6	0.3, 1.9	7	10	2.9/10	0.6	0.3, 1.8
	Quaternary ammonium	14	20	11.2/26	1.8	1.0, 3.4	11	16	7.3/22	1.0	0.5, 1.9
	Thiodiazine	6	8	9.1/10	1.2	0.6, 2.3	14	21	6.4/21	1.1	0.6, 2.1
	Butylate	17	23	14.7/26	0.7	0.3, 1.3	24	35	10.0/37	1.4	0.8, 2.5
	Substituted urea	16	22	17.5/23	0.8	0.4, 1.5	16	24	11.3/23	1.0	0.6, 1.8
	Triazine	40	49	35.7/77	1.0	0.5, 1.9	43	59	24.3/62	1.1	0.5, 2.2
	Cyanazine	30	39	19.7/29	2.6	1.4, 4.9	26	38	13.5/40	1.0	0.5, 1.8
	Triazinone	28	38	20.8/29	2.8	1.5, 5.0	19	28	14.2/31	0.5	0.3, 1.0
	Methidathion	35	46	35.2/46	1.0	0.6, 1.7	37	51	24.7/51	0.7	0.4, 1.2
Organochlorines	Carbamate	21	27	12.9/26	1.7	1.3, 2.2	21	31	8.9/31	1.1	0.6, 2.0
	Carbofuran	21	27	12.9/26	1.7	1.3, 2.2	21	31	8.9/31	1.1	0.6, 2.0
	Aldrin	25	31	8.8/34	1.2	0.7, 2.3	22	31	8.1/31	1.2	0.6, 2.0
	Chlordane	19	21	12.7/31	0.7	0.4, 1.4	23	32	9.1/32	0.8	0.4, 1.5
	Dieldrin	9	13	3.1/18	0.9	0.4, 2.0	8	11	2.3/11	0.5	0.2, 1.8
	DDT	25	33	12.6/20	1.7	1.0, 3.0	29	40	8.7/40	1.0	0.5, 1.9
	Heptachlor	15	21	7.1/24	1.0	0.6, 2.2	16	23	5.1/23	0.7	0.4, 1.4
	Lindane	14	19	8.8/23	1.2	0.6, 2.3	19	28	8.4/28	1.4	0.8, 2.5
	Toxaphene	5	7	6.7/10	0.3	0.2, 1.0	9	13	4.6/13	0.9	0.3, 1.3

SYNG-PQ-00481046

The Optical Fractionator Method of Stereology



$$N = \sum Q^- \times 1/ssf \times 1/asf \times 1/tsf$$

13

syngenta

SYNG-PQ-00481049

Proposed Exponent Protocol

- 1) Toxicokinetic Study (single dose of 7.4 & 74 $\mu\text{mol/kg}$ - propose to dose the Gramoxone formulation)

PND 5 mice
Saline
0.3 mg/kg PQ
PQ + 1 mg/kg maneb
i.p. & oral

Adult mice
Saline
10 mg/kg PQ
PQ + 30 mg/kg maneb
i.p., oral, dermal & inhalation
(direct application to the nasal epithelium)

Concentration of PQ in plasma and different brain regions using [^{14}C]-PQ and autoradiography (WBA for young mice)

- 2) Use PBPK modelling to determine the equivalent human exposure doses via the relevant routes (dermal / oral - seem to think inhalation route is relevant).

14

syngenta

SYNG-PQ-00481050

Proposed Exponent Protocol

- 3) Toxicology Study (i.p. dosing to mice using the Cory-Slechta dosing regimen)

PND 5-19 mice
Saline
PQ
maneb
PQ + maneb
(leave till 8 months old)

PND 5-19 & as adults
(8 months old)
Saline
PQ
maneb
PQ + maneb

Adult mice
(8 months old)
Saline
PQ
maneb
PQ + maneb

PND 5-19 & as adults
Saline
PQ
maneb
PQ + maneb
(leave till 16 months old)

Neuronal Cell Loss

(Stereology - Jim O'Callaghan (CDC); silver staining - Bob Switzer (Neuroscience Associates) & Daryl Thake (Monsanto))

3 different doses to both male & female mice:

- Human equivalent dose (from PBPK modelling)
- Mid dose
- "High" Cory-Slechta dose (0.3 or 10 mg/kg PQ, 1 or 30 mg/kg maneb)

15

syngenta

SYNG-PQ-00481051


10%	10%	NO	-----	McCormack et al (2002)
5 mg/kg	36%	-----	YES +	Brooks et al (1999)
5 mg/kg	18%	NO	-----	McCormack et al (2002)
5 mg/kg (for 4 wks)	-----	-----	NO	Thiruchelvam et al (2000 b)
10 mg/kg	23-24%	NO	NO	SYNGENTA CTL
10 mg/kg	61%	-----	YES ++	Brooks et al (1999)
10 mg/kg	28%	NO	-----	McCormack et al (2002)
10 mg/kg	26%	-----	-----	McCormack et al (2003)
10 mg/kg	25-35%	-----	-----	Manning-Boger et al (2003)
10 mg/kg (for 4 wks)	-----	8%	NO	Thiruchelvam et al (2000 b)
2 x 10 mg/kg	14%	NO	NO	SYNGENTA CTL
2 x 10 mg/kg	21%	10% (DOPAC & HVA 15-20%)	NO	Thiruchelvam et al (2002)
2 x 10 mg/kg	31%	NO	YES at 24 hrs NO at 3 months	Thiruchelvam et al (2003)
2 x 10 mg/kg (18 mth old)	38%	NO	YES at 3 month	Thiruchelvam et al (2003)
2 x 10 mg/kg (for 6 wks)	9%	7%	NO	Thiruchelvam et al (2000 a)
2 x 10 mg/kg (for 12 wks)	-----	NO	YES but recovery by 24 hrs	Reeves et al (2003)

16

syngenta

SYNG-PQ-00481052

Nigrostriatal dopaminergic system




17

syngenta

SYNG-PQ-00481053


Apparent Structural Similarity Of Paraquat With MPTP & MPP⁺

Paraquat




Hydrophilic, charged di-cation

MPTP



Monoamine, uncharged lipophilic molecule

MPP⁺



Charged, neurotoxic metabolite of MPTP

18

syngenta

SYNG-PQ-00481054